7-31-20 At the end of May there was a significant breakthrough in understanding of COVID antibodies which was not widely reported: a Swiss study from Zurich led by Professor Onur Boyman74 demonstrated that a large proportion of the population had a natural immunity through existing antibodies on the mucous membrane (IgA) or cellular immunity (T cells), likely to have been acquired through previous exposure to coronaviruses such as influenza or the common cold (the absence of exposure to previous coronavirus is now thought to explain the opposite effect in 1918) 75. The study found that the presence of (IgG and IgM) antibodies generated on infection which tests had previously focused on, were NOT in fact required to defeat the virus and that existing (IgA and T cell) antibodies gave a natural immunity. Moreover, the population with this natural immunity was demonstrated to be five times greater than those with the IgG and IgM antibodies on which tests had hitherto focused….
we still hear the daily groupthink catechism that the only “long-term solution” to beating COVID is a vaccine, often without any understanding of the historic limitations of vaccines particularly in the immunisation against coronaviruses 109. …A significant obstacle to a successful vaccine is the rapid degradation of IgG and IgM COVID antibodies meaning that even a successful vaccine might not give any benefit for longer than a few weeks. As the CEO of world leading testing company Roche Diagnostics recently commented: “What appears to happen is that people do lose antibodies over time. And that of course poses the question, will vaccines actually work if you lose antibodies”110….
Leading Swiss epidemiologist Pietro Vernazza has demonstrated that the high-risk group is least likely to respond to the vaccine since their immune system is already impaired 112. Whilst it is possible for vaccine trials to demonstrate antibody responses, whether these will have any practical lasting benefits in reducing COVID mortality risk which are tolerable for the population group most at risk from COVID is unlikely….
There is a more fundamental question of whether a vaccination program for the entire population is at all desirable, given that most of the population has a natural immunity, only a small cohort develops symptoms, an even smaller cohort at risk of hospitalisation. -B. Norris https://blog.argonautcapital.co.uk/articles/2020/07/27/the-biggest-fraud-part-2-the-vaccine-swindle/
75 https://reaction.life/we-may-already-have-herd-immunity-an-interview-with-professor-sunetra-gupta/
110 Thomas Schinecker, CEO, Roche Diagnostics. Roche Q2 Conf Call, 23 July 2020 https://www.roche.com/investors/agenda/hy-2020-replay.htm
112 https://infekt.ch/2020/05/corona-impfung-als-ultimative-rettung/ ..............................
The United States will pay up to $2.1 billion “for development including clinical trials, manufacturing, scale-up and delivery" of the vaccine, the two companies based in Europe said in a statement. Sanofi will get the bulk of the funds. https://www.newsmax.com/newsfront/britain-vaccine/2020/07/31/id/979989/
No comments:
Post a Comment